Skip to main content
Log in

SAE-related costs lower with larotrectinib than with entrectinib

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. International Society for Pharmacoeconomics and Outcomes Research

  2. 2019 US dollars

Reference

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

SAE-related costs lower with larotrectinib than with entrectinib. PharmacoEcon Outcomes News 855, 27 (2020). https://doi.org/10.1007/s40274-020-6892-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6892-4

Navigation